...
首页> 外文期刊>Pharmacopsychiatry >On the effects of partial agonists of dopamine receptors for the treatment of schizophrenia.
【24h】

On the effects of partial agonists of dopamine receptors for the treatment of schizophrenia.

机译:关于多巴胺受体部分激动剂治疗精神分裂症的作用。

获取原文
获取原文并翻译 | 示例

摘要

The aim of this paper is to describe the possible effects of antipsychotic drugs on neurotransmitter interactions in cortico-striatal circuits related to schizophrenia symptoms, with special emphasis on the action of partial agonists of dopamine and serotonin receptors. Partial agonists are characterised by a high affinity and a low intrinsic activity. However, since the intrinsic activity of the ligand-bound receptor is still higher than after antagonist binding, partial agonists can act as agonists or as antagonists, depending on the endogenous levels of dopamine and receptor reserve. Aripiprazole is a partial agonist at dopamine D2-receptors and at serotonin 1A-receptors, and is currently the only marketed drug of this class of agents that is used for the treatment of schizophrenia.
机译:本文的目的是描述抗精神病药对与精神分裂症症状相关的皮质-纹状体回路中神经递质相互作用的可能作用,特别强调多巴胺和5-羟色胺受体的部分激动剂的作用。部分激动剂的特征在于高亲和力和低内在活性。但是,由于与配体结合的受体的内在活性仍然高于拮抗剂结合后的活性,因此取决于多巴胺的内源性水平和受体储备,部分激动剂可以充当激动剂或拮抗剂。阿立哌唑是多巴胺D2受体和血清素1A受体的部分激动剂,目前是此类药物中唯一可用于治疗精神分裂症的上市药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号